<DOC>
	<DOCNO>NCT02959476</DOCNO>
	<brief_summary>This study evaluate Ropivacaine 0.2 % Pre-Filled Dispenser treatment post-surgical pain patient undergoing Cesarean delivery . Half patient receive Ropivicaine half receive placebo .</brief_summary>
	<brief_title>Ropivacaine 0.2 % Pre-Filled Dispenser Treatment Postsurgical Pain Patients Undergoing Cesarean Delivery</brief_title>
	<detailed_description />
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Ropivacaine</mesh_term>
	<criteria>Complete inform consent process document sign informed consent form ( ICF ) . Be generally good health classify either PS1 PS2 American Society Anesthetists ( ASA ) Physical Status Classification System . Have single birth pregnancy . Can parous nulliparous . Be schedule Cesarean Delivery Subjects undergoing emergency Cesarean Delivery eligible participation study . In event subject sign ICF ( randomize ) , C section plan emergency C section delivery , subject consider screen failure . In unlikely event subject sign ICF randomize study , C section plan emergency C section delivery , subject continue study plan . Be willing complete pain assessment accord protocol return clinic schedule , need . Have uncontrolled medical condition , serious intercurrent illness , clinically significant general health condition , extenuate circumstance may significantly decrease study compliance otherwise preclude participation study . Have clinically significant abnormal electrocardiogram ( ECG ) screening determine Investigator . Have history medical condition surgical procedure would alter absorption , distribution , metabolism , excretion ropivacaine . Have , opinion investigator , clinically significant abnormality clinical laboratory value ( urinalysis , hematology chemistry ) screening . Have make donation ( standard donation amount ) blood blood product ( exception plasma note ) within 56 day prior Day 1 . Weigh great 100 kg ( 220 lb ) . Have make plasma donation within 7 day prior Day 1 . Have know allergy hypersensitivity anesthetic ( eg . Ropivacaine ) , acetaminophen , nonsteroidal anti inflammatory drug ( NSAIDs , eg , ibuprofen naproxen , ketorolac ) . Not able willing discontinue prohibit medication list within allotted time surgery throughout duration participation study . monoamine oxidase inhibitor ( MAOIs ) within past 30 day anticonvulsant , tricyclic antidepressant ( TCAs ) , neuroleptic , serotoninnorepinephrine reuptake inhibitor ( SNRIs ) , well selective serotonin reuptake inhibitor ( SSRIs ) ( unless SSRIs prescribe depression and/or anxiety subject stable dose least 30 day prior screen visit ) ; Corticosteroids : Oral injectable corticosteroid must discontinue 3 month prior surgery ; nasal , inhaled topical corticosteroid allow ; Use concurrent therapy could interfere evaluation efficacy safety parameter opinion investigator ( eg , drug , investigator 's opinion , may exert significant analgesic property ) , except rescue medication . Have history seizure history serious head injury . Must member vulnerable population define Code Federal Regulations Title 45 , Part 46 , Delivery 46.111 ( b ) , include limited employee ( temporary , parttime , fulltime , etc . ) family member research staff conduct study , Sponsor , Clinical Research Organization . Have previously participate clinical trial use ropivacaine . Have history major mental illness opinion Investigator may affect ability subject participate study . Institutionalized subject eligible participation .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Postoperative pain</keyword>
	<keyword>Postsurgical pain</keyword>
</DOC>